Related Experiment Video

Updated: May 18, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Antithrombotic treatment of atrial fibrillation: new insights

J Y Le Heuzey1

  • 1Georges Pompidou Hospital, René Descartes University, Paris. jean-yves.le-heuzey@egp.aphp.fr

Thrombosis Research
|October 3, 2012
PubMed

Insights

Atrial fibrillation (AF) is a growing public health concern. New oral anticoagulants significantly reduce stroke risk compared to older treatments, but require caution in patients with kidney issues.

Area of Science:

  • Cardiology
  • Public Health
  • Pharmacology

Background:

  • Increasing incidence and prevalence of atrial fibrillation (AF) due to population aging.
  • AF poses a significant public health challenge, increasing stroke risk five-fold.
  • Traditional antithrombotic treatment for AF involves vitamin K antagonists, reducing stroke risk by approximately 60%.

Purpose of the Study:

  • To review the efficacy and safety of new oral anticoagulants for atrial fibrillation.
  • To compare new oral anticoagulants with traditional treatments for stroke prevention in AF patients.
  • To highlight the role of novel anticoagulant therapies in managing AF.

Main Methods:

  • Review of landmark clinical trials (RE-LY, ROCKET AF, AVERROES, ARISTOTLE) evaluating new oral anticoagulants.
  • Analysis of data on stroke risk reduction and intracranial hemorrhage incidence.
  • Consideration of drug pharmacokinetics, particularly renal elimination.

Main Results:

  • New oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, demonstrate significant efficacy in preventing stroke in AF patients.
  • These novel agents have shown a reduction in intracranial hemorrhages compared to older treatments.
  • Clinical trials confirm the effectiveness of new oral anticoagulants in reducing stroke risk.

Conclusions:

  • New oral anticoagulants are poised to become a cornerstone in the treatment of atrial fibrillation.
  • Careful consideration of renal function is crucial when prescribing these medications due to kidney elimination.
  • These agents offer improved safety and efficacy profiles for stroke prevention in AF.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...